Clinical Trial Update: Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan

View source ↗

Summary

This clinical trial update presents long-term outcomes of agalsidase beta treatment in Fabry disease patients with the IVS4 mutation in Taiwan; the study is act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• FABRAZYME (Agalsidase beta)

Snippet

Sponsor: Sanofi | Conditions: Fabry Disease | Status: ACTIVE_NOT_RECRUITING